皮膚真菌症の世界市場

皮膚真菌症の世界市場は2030年までに166億米ドルに到達

2024年に141億米ドルと推定される皮膚真菌症の世界市場は、2024～2030年の分析期間においてCAGR 2.7%で成長し、2030年には166億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである副腎皮質ステロイドは、CAGR 1.8%を記録し、分析期間終了時には40億米ドルに達すると予測されます。Corticosteroid-sparing Agents（副腎皮質ステロイド節約薬）セグメントの成長率は、分析期間中CAGR 3.2％と推定されます。

米国市場は38億米ドルと推定、中国はCAGR 4.9％で成長予測

米国の皮膚真菌症市場は、2024年に38億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに32億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.0%と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の皮膚真菌症市場- 主要動向と促進要因まとめ

なぜ皮膚真菌症は世界的に広範な皮膚科の課題として浮上しているのか？

皮膚真菌症は、一般的に皮膚、毛髪、爪の表在性真菌感染症と呼ばれ、世界で最も蔓延している皮膚科疾患の一つとして浮上しており、毎年数億人が罹患しています。この真菌感染症には、足白癬（水虫）、体部白癬（白癬菌）、爪真菌症（爪カビ）などがあり、温暖で湿度の高い環境で増殖し、特に熱帯・亜熱帯地域に多いです。世界の気温の上昇、都市部の人口密度の増加、混雑した生活環境における不衛生などが、感染率を着実に上昇させています。特に顔や頭皮、爪など目に見える部分に発症した場合、不快感を与えるだけでなく、社会的なスティグマにつながることも多いです。糖尿病、肥満、免疫抑制状態、抗生物質や副腎皮質ステロイドの長期使用などの要因は、特に高齢者層において、皮膚真菌症への感受性を著しく高める。さらに、スポーツジムやプール、共同宿泊施設などの共同利用が増加し、感染のリスクが高まっています。皮膚真菌症は、ほとんどの場合生命を脅かすものではないにもかかわらず、効果的な治療がなされなければ、持続性・再発性の可能性があり、正確な診断と長期的な管理の必要性が高まっています。世界の多くの地域で皮膚科医療に対する意識が高まり、アクセスが改善されるにつれ、市販薬や家庭での治療のみに頼らず、医療を求める人が増えています。このように皮膚真菌症の負担が増大していることから、皮膚科は公衆衛生システムや医薬品開発者の注目の的となっています。

診断と治療の進歩は、皮膚真菌症の管理をどのように変えているのか？

皮膚科学的診断と抗真菌治療における最近の進歩は、皮膚真菌症の管理を再構築し、治療をより効果的で、利用しやすく、患者に適したものにしています。臨床検査と真菌培養による伝統的な診断は、ダーモスコピー、水酸化カリウムによる直接顕微鏡検査、ポリメラーゼ連鎖反応（PCR）アッセイといった、原因菌をより迅速かつ正確に同定できるより高度な技術によって補完されつつあります。迅速な診断ツールにより、合併症や再発の予防に不可欠な早期介入が可能となりました。治療面では、新しい抗真菌薬の開発により、外用薬、全身薬ともに患者の予後が改善され、治療期間も短縮されています。テルビナフィンやイトラコナゾールのような経口剤は頑固な感染症や広範囲の感染症に広く使用され、新世代の外用クリームやスプレーは局所的な症状に効果的な選択肢を提供しています。特に、従来ドラッグデリバリーが困難であった爪や頭皮の感染症に対しては、皮膚への浸透性とバイオアベイラビリティを高める革新的な製剤が人気を集めています。さらに、抗真菌剤と抗炎症剤や角質溶解剤を併用することで、感染症だけでなく、かゆみや鱗屑などの関連症状にも対応する治療法も一般的になりつつあります。また、特定の抗真菌薬に対する耐性も懸念されており、天然または植物由来の抗真菌薬や免疫増強剤などの代替治療法の研究が進められています。遠隔皮膚科プラットフォームやAIを活用した診断ツールは、十分な治療を受けられない地域でタイムリーな治療を提供するためにますます活用されるようになっており、それによって治療へのアクセスが改善されています。このような技術や医薬品の開発により、医療が近代化され、より的を絞った持続可能な疾病対策への道が開かれつつあります。

皮膚真菌症治療の成長と範囲に影響を与えている市場動向とは？

いくつかの市場動向は、ヘルスケア提供、消費者行動、医薬品開発における幅広いシフトを反映し、皮膚真菌症治療領域における拡大やイノベーションに影響を与えています。重要な動向のひとつは、認知度、利便性、入手しやすさの向上により、市販の抗真菌薬への関心が高まっていることです。消費者は自己診断し、外用クリーム、スプレー、パウダーを使用して初期治療を開始する傾向が強くなっており、症状が持続したり悪化したりしない限り、受診を遅らせることが多いです。この動向により、メーカーはブランドの差別化、使いやすい包装、感染とスキン炎症の両方に対応する多目的製剤への投資を促しています。もう一つの重要な動向は、電子薬局やオンラインヘルスプラットフォームの台頭で、遠隔地や十分なサービスを受けられない地域の消費者が抗真菌治療にアクセスしやすくなっています。また、特に軽症の感染症や再発性の感染症に対して、合成医薬品に代わる治療法を求める人が増えているため、ハーブや自然療法への関心も高まっています。一方、臨床現場では、個別化医療の動向により、真菌の種類、感染部位、患者の併存疾患に基づいて、よりオーダーメイドの治療レジメンが行われるようになってきています。また、多くの地域で新薬の承認に対する規制の枠組みが強化されつつあり、革新的な抗真菌治療薬の市場参入が加速しています。医療機関セグメントでは、病院や診療所がより厳格な感染管理対策を採用し、皮膚真菌症のアウトブレイクをより効率的に管理するために包括的な真菌学サービスを提供しています。また、学術機関と製薬企業との連携により、新たな抗真菌剤、耐性メカニズム、宿主と病原体の相互作用に関する研究が推進されています。これらの動向は、皮膚真菌症を管理する上で、有効性、アクセス性、革新性を優先するダイナミックな市場環境を形成しています。

皮膚真菌症市場の世界的成長の主な促進要因は？

皮膚真菌症市場の成長の原動力は、疫学的、臨床的、環境的、商業的要因の組み合わせであり、これらの要因が相まって、皮膚真菌症が世界の影響を及ぼし、効果的な治療に対するニーズが拡大していることを裏付けています。世界の気温と湿度の上昇は、特に衛生状態が悪く換気が制限された都市部において、真菌の増殖により適した環境を作り出しています。人口の高齢化や糖尿病、がん、免疫抑制状態の蔓延といった人口動態の変化は、真菌感染症、特に慢性または再発性の真菌感染症に対する脆弱性を高めています。世界の旅行の拡大、共同生活空間、スポーツジム、公共プールの利用の増加は、以前はリスクが低いと考えられていた地域でも、感染率を高める一因となっています。臨床面では、ヘルスケア専門家や患者の意識の向上が早期診断と治療アドヒアランスの向上につながり、処方薬と市販薬の両方の抗真菌剤需要を促進しています。診断ツールや治療製剤における技術革新は、より正確で効果的な管理戦略を可能にし、製薬会社やバイオテクノロジー企業からの投資を引き付けています。さらに、eコマースや遠隔医療の台頭により、特に低資源環境において、治療へのアクセスが改善され、患者参加も容易になっています。衛生、予防医療、皮膚科教育に重点を置いた政府の取り組みも、真菌感染症に対する公衆の反応性を高める役割を果たしています。主要な市場参入企業による強固な流通網と競争力のある価格戦略が、抗真菌治療薬の世界の普及をさらに後押ししています。これらの多様な促進要因が相まって、皮膚真菌症市場は、革新性、アクセシビリティ、臨床効果を核に、安定した成長を続けています。

セグメント

薬剤クラス別（副腎皮質ステロイド、副腎皮質ステロイド温存剤、免疫抑制剤、免疫調節剤、抗真菌剤、その他薬剤）、投与経路別（経口投与、非経口投与、局所投与、その他投与経路）、エンドユーザー別（病院エンドユーザー、専門クリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例

• Almirall, S.A.
• AmDerma Pharmaceuticals
• Bausch Health Companies Inc.
• Bayer AG
• Cadila Healthcare Ltd.（Zydus）
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Galderma S.A.
• Glenmark Pharmaceuticals Ltd.
• GSK plc（GlaxoSmithKline）
• Johnson & Johnson
• Kaken Pharmaceutical Co., Ltd.
• LEO Pharma A/S
• Lupin Ltd.
• Medimetriks Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Dermatomycosis Market to Reach US$16.6 Billion by 2030

The global market for Dermatomycosis estimated at US$14.1 Billion in the year 2024, is expected to reach US$16.6 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Corticosteroid-sparing Agents segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 4.9% CAGR

The Dermatomycosis market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Dermatomycosis Market - Key Trends & Drivers Summarized

Why Is Dermatomycosis Emerging as a Widespread Dermatological Challenge Globally?

Dermatomycosis, commonly referred to as superficial fungal infection of the skin, hair, or nails, is emerging as one of the most prevalent dermatological conditions worldwide, affecting hundreds of millions of people annually. This group of fungal infections, including tinea pedis (athlete’s foot), tinea corporis (ringworm), and onychomycosis (nail fungus), thrives in warm, humid environments and is particularly common in tropical and subtropical regions. Rising global temperatures, increasing urban density, and poor hygiene in crowded living conditions are all contributing to a steady rise in infection rates. The condition is not only a source of discomfort but also often leads to social stigma, particularly when it affects visible parts of the body such as the face, scalp, or nails. Factors such as diabetes, obesity, immunosuppressive conditions, and long-term use of antibiotics or corticosteroids significantly increase susceptibility to dermatomycosis, especially among elderly populations. In addition, the increased use of communal facilities like gyms, swimming pools, and shared accommodations has heightened the risk of transmission. Despite being non-life-threatening in most cases, dermatomycosis can be persistent and recurrent if not treated effectively, leading to a growing need for accurate diagnosis and long-term management. As awareness rises and access to dermatological services improves in many parts of the world, more individuals are seeking medical treatment rather than relying solely on over-the-counter remedies or home-based interventions. This growing burden of dermatomycosis is placing it firmly on the radar of public health systems and pharmaceutical developers alike.

How Are Advancements in Diagnosis and Treatment Reshaping the Management of Dermatomycosis?

Recent advancements in dermatological diagnostics and antifungal therapies are reshaping the management of dermatomycosis, making treatments more effective, accessible, and patient-specific. Traditional diagnosis through clinical examination and fungal culture is increasingly being supplemented by more advanced techniques such as dermoscopy, direct microscopic examination with potassium hydroxide, and polymerase chain reaction (PCR) assays, which allow for faster and more accurate identification of causative organisms. Rapid diagnostic tools have enabled earlier intervention, which is critical in preventing complications and recurrence. On the treatment front, the development of newer antifungal agents, both topical and systemic, is improving patient outcomes and reducing the duration of treatment. Oral agents like terbinafine and itraconazole are widely used for stubborn or widespread infections, while new-generation topical creams and sprays provide effective options for localized conditions. Innovative formulations that enhance skin penetration and bioavailability are gaining popularity, especially for nail and scalp infections where drug delivery has traditionally been a challenge. In addition, combination therapies that include antifungal agents with anti-inflammatory or keratolytic ingredients are becoming common to address both the infection and associated symptoms like itching and scaling. Resistance to certain antifungal drugs is also a growing concern, prompting research into alternative treatments, including natural or plant-derived antifungals and immune-boosting agents. Teledermatology platforms and AI-powered diagnostic tools are increasingly being utilized to deliver timely care in underserved areas, thereby improving access to treatment. These technological and pharmaceutical developments are modernizing dermatomycosis care and paving the way for more targeted and sustainable approaches to disease control.

What Market Trends Are Influencing the Growth and Scope of Dermatomycosis Treatments?

Several market trends are influencing the expansion and innovation within the dermatomycosis treatment space, reflecting broader shifts in healthcare delivery, consumer behavior, and pharmaceutical development. One significant trend is the growing inclination toward over-the-counter antifungal medications, driven by greater awareness, convenience, and accessibility. Consumers are more likely to self-diagnose and begin initial treatment using topical creams, sprays, or powders, often delaying clinical consultation unless symptoms persist or worsen. This trend has prompted manufacturers to invest in brand differentiation, user-friendly packaging, and multipurpose formulations that address both infection and skin irritation. Another key trend is the rise of e-pharmacies and online health platforms, which has made antifungal treatments more accessible to consumers in remote or underserved locations. There is also increasing interest in herbal and natural remedies, as more individuals seek alternatives to synthetic pharmaceuticals, particularly for mild or recurrent infections. Meanwhile, in clinical settings, the trend toward personalized medicine is leading to more tailored treatment regimens based on fungal species, site of infection, and patient comorbidities. Regulatory frameworks in many regions are becoming more supportive of novel drug approvals, allowing for faster market entry of innovative antifungal therapies. In the institutional segment, hospitals and clinics are adopting stricter infection control measures and offering comprehensive mycology services to manage dermatomycosis outbreaks more efficiently. Partnerships between academic institutions and pharmaceutical companies are driving research into new antifungal agents, resistance mechanisms, and host-pathogen interactions. These trends are collectively shaping a dynamic market environment that prioritizes effectiveness, accessibility, and innovation in managing dermatomycosis.

What Are the Primary Drivers Behind the Global Growth of the Dermatomycosis Market?

The growth in the dermatomycosis market is driven by a combination of epidemiological, clinical, environmental, and commercial factors that together underline the condition’s global impact and the expanding need for effective treatments. Rising global temperatures and humidity levels are creating more favorable environments for fungal proliferation, especially in urban areas with poor sanitation and limited ventilation. Demographic shifts such as aging populations and rising prevalence of diabetes, cancer, and immunosuppressive conditions are increasing vulnerability to fungal infections, particularly chronic or recurrent forms of dermatomycosis. The expansion of global travel and increased use of communal living spaces, gyms, and public pools are contributing to higher transmission rates, even in regions previously considered low-risk. From a clinical standpoint, improved awareness among healthcare professionals and patients is leading to earlier diagnosis and better treatment adherence, fueling demand for both prescription and over-the-counter antifungal products. Technological innovations in diagnostic tools and therapeutic formulations are enabling more precise and effective management strategies, attracting investment from pharmaceutical and biotech companies. Additionally, the rise of e-commerce and telehealth is improving treatment access and facilitating patient engagement, especially in low-resource settings. Government initiatives focused on hygiene, preventive care, and dermatological education are also playing a role in increasing public responsiveness to fungal infections. The presence of robust distribution networks and competitive pricing strategies by key market players further supports the global proliferation of antifungal treatments. Together, these diverse drivers are ensuring that the dermatomycosis market continues to grow steadily, with innovation, accessibility, and clinical effectiveness at its core.

SCOPE OF STUDY:

The report analyzes the Dermatomycosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs); Administration Route (Oral Administration, Parenteral Administration, Topical Administration, Other Administration Routes); End-User (Hospitals End-User, Specialty Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Almirall, S.A.
• AmDerma Pharmaceuticals
• Bausch Health Companies Inc.
• Bayer AG
• Cadila Healthcare Ltd. (Zydus)
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Galderma S.A.
• Glenmark Pharmaceuticals Ltd.
• GSK plc (GlaxoSmithKline)
• Johnson & Johnson
• Kaken Pharmaceutical Co., Ltd.
• LEO Pharma A/S
• Lupin Ltd.
• Medimetriks Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Dermatomycosis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Superficial Fungal Infections Throws the Spotlight on Dermatomycosis Treatments
  • Increasing Prevalence in Tropical and Humid Regions Expands the Addressable Market for Antifungal Therapies
  • Growing Awareness of Skin Health and Hygiene Drives Early Diagnosis and Over-the-Counter Treatment Uptake
  • Expanding Geriatric and Immunocompromised Populations Strengthens the Business Case for Chronic Infection Management
  • Advancements in Topical and Systemic Antifungal Formulations Propel Market Innovation
  • Availability of Combination Therapies Accelerates Demand for Multifunctional Treatment Regimens
  • Antifungal Resistance Concerns Create Opportunities for Novel Drug Classes and Research Investments
  • E-Commerce and Online Pharmacies Spur Growth in Direct-to-Consumer Dermatology Products
  • Outreach and Awareness Campaigns by Health Agencies Drive Prevention and Early Intervention
  • Rising Demand for Natural and Herbal Antifungals Opens New Product Development Channels
  • Climate Change and Global Travel Trends Contribute to the Geographic Spread of Dermatomycosis
  • Integration of AI and Digital Diagnostics Drives Early Detection and Tailored Treatment Plans
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dermatomycosis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dermatomycosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroid-sparing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Corticosteroid-sparing Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Corticosteroid-sparing Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immunosuppressive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immunosuppressive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Immunosuppressive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunomodulator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Immunomodulator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Antifungals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Antifungals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Antifungals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• JAPAN
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• CHINA
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: China 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• EUROPE
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Dermatomycosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• FRANCE
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: France 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: France 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• GERMANY
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Germany 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Italy 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: UK 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Spain 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Russia 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Dermatomycosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Australia 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• INDIA
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: India 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: India 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: South Korea 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Dermatomycosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Argentina 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Brazil 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Mexico 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Dermatomycosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Dermatomycosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Iran 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Israel 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: UAE 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
• AFRICA
  • Dermatomycosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Dermatomycosis by Drug Class - Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Dermatomycosis by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals and Other Drugs for the Years 2014, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Dermatomycosis by Administration Route - Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Dermatomycosis by Administration Route - Percentage Breakdown of Value Sales for Other Administration Routes, Oral Administration, Parenteral Administration and Topical Administration for the Years 2014, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Dermatomycosis by End-user - Hospitals End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Africa 16-Year Perspective for Dermatomycosis by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION